Brainstorm Cell Therapeutics Inc.

3.1100.00Vol 566.22K1Y Perf -49.92%
Apr 20th, 2021 16:00 DELAYED
BID3.05 ASK3.08
Open3.11 Previous Close3.11
Pre-Market- After-Market3.11
 - -  - -%
Target Price
11.50 
Analyst Rating
Strong Buy 1.00
Potential %
269.78 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap111.09M 
Earnings Rating
Buy
Price Range Ratio 52W %
0.93 
Earnings Date
6th May 2021

Today's Price Range

2.973.22

52W Range

2.9717.95

5 Year PE Ratio Range

-10.70-6.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-11.65%
1 Month
-25.42%
3 Months
-42.83%
6 Months
-67.30%
1 Year
-49.92%
3 Years
-9.86%
5 Years
42.01%
10 Years
-25.95%

TickerPriceChg.Chg.%
BCLI3.110.00000.00
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.48-0.3722.92
Q03 2020-0.24-0.1441.67
Q02 2020-0.24-0.25-4.17
Q01 2020-0.23-0.32-39.13
Q04 2019-0.21-0.34-61.90
Q03 2019-0.16-0.25-56.25
Q02 2019-0.11-0.23-109.09
Q01 2019-0.06-0.24-300.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.2781.38Positive
6/2021 QR-0.2569.88Positive
12/2021 FY-1.54--
12/2022 FY-0.88--
Next Report Date6th May 2021
Estimated EPS Next Report-0.27
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume566.22K
Shares Outstanding35.72M
Trades Count2.86K
Dollar Volume4.02M
Avg. Volume1.08M
Avg. Weekly Volume523.37K
Avg. Monthly Volume1.01M
Avg. Quarterly Volume1.17M

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock closed at 3.11 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 567.40K shares and market capitalization of 111.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 40 people. Brainstorm Cell Therapeutics Inc. CEO is Chaim Lebovits.

The one-year performance of Brainstorm Cell Therapeutics Inc. stock is -49.92%, while year-to-date (YTD) performance is -31.35%. BCLI stock has a five-year performance of 42.01%. Its 52-week range is between 2.97 and 17.95, which gives BCLI stock a 52-week price range ratio of 0.93%

Brainstorm Cell Therapeutics Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 3.15, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -108.99%, a ROC of -225.59% and a ROE of -287.15%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Brainstorm Cell Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Brainstorm Cell Therapeutics Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Brainstorm Cell Therapeutics Inc. is Strong Buy (1), with a target price of $11.5, which is +269.78% compared to the current price. The earnings rating for Brainstorm Cell Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Brainstorm Cell Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Brainstorm Cell Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.99, ATR14 : 0.42, CCI20 : -179.92, Chaikin Money Flow : -0.37, MACD : -0.68, Money Flow Index : 48.36, ROC : -18.80, RSI : 32.22, STOCH (14,3) : 8.42, STOCH RSI : 0.00, UO : 35.53, Williams %R : -91.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Brainstorm Cell Therapeutics Inc. in the last 12-months were: David Setboun (Buy at a value of $64 740), Sankesh Abbhi (Buy at a value of $1 215 318)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

CEO: Chaim Lebovits

Telephone: +1 201 488-0460

Address: 1325 Avenue of Americas, New York 10019, NY, US

Number of employees: 40

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

63%38%

Bearish Bullish

57%43%

Bearish Bullish

50%50%

News

Stocktwits